AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: Hospital-based cohort studies

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Luz, Paula M ^a   Bruyand, Mathias ^b,c   Ribeiro, Sayonara ^a   Bonnet, Fabrice ^b,c   Moreira, Ronaldo I ^a   Hessamfar, Mojgan ^b,c   Campos, Dayse P ^a   Greib, Carine ^d   Cazanave, Charles ^e   Veloso, Valdilea G ^a   Dabis, François ^b,c   Grinsztejn, Beatriz ^a   Chêne, Geneviève ^b,c,p   Breilh, D ^p   Dupon, M ^p   Fleury, H ^p   Malvy, D ^p   Mercie P ^p   Pellegrin, I ^p   Morlat, P ^p   Neau, D ^p   Pellegrin, J L ^p   Thiebaut R ^p   Bouchet, S ^p   Gaborieau, V ^p   Lacoste, D ^p   Tchamgoue S ^p   Wittkop, L ^p   Lawson Ayayi, S ^f   Bernard, N ^g   Vandenhende, M A ^g   Dauchy, F A ^g   Dutronc, H ^g   Duffau, P ^g   Roger Schmeltz, J ^g   Pistone, T ^g   Receveur, M C ^g   Ochoa, A ^g   Vareil, M O ^g   Viallard, J F ^g   Lazaro, E ^g   Lafon, M E ^g   Reigadas, S ^g   Trimoulet, P ^g   Molimard, M ^g   Titier, K ^g   Moreau, J F ^g   Haramburu, F ^g   Miremont Salame G ^g   Dupont, A ^h   Gerard, Y ⁱ   Caunegre L ⁱ   Andre K ⁱ   Bonnal, F ^j   Farbos, S ^j   Gemain, M C ^j   Ceccaldi, J ^k   Caubet, O ^k   De Witte, S ^l   Courtault, C ^l   Monlun, E ^m   Lataste, P ⁿ   Meraud, J P ⁿ   Chossat, I ^o   Blaizeau, M J ^p   Conte, V ^p   Decoin, M ^p   Delaune, J ^p   Delveaux, S ^p   Diarra, F ^p   D'Ivernois, C ^p   Frosch, A ^p   Geffard, S ^p   Hanappier, C ^p   Lenaud, E ^p   Leleux, O ^p   Marec, Le ^p   Leray, J ^p   Louis, I ^p   Palmer, G ^p   Pougetoux, A ^p   Sicard, X ^p   Touchard, D ^p   Uwamaliya Nziyumvira, B ^p   more..

^a Funda??o Oswaldo Cruz   (Brazil)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c Centre of Clinical Investigation Clinical Epidemiology   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e HÔPITAL PELLEGRIN   (France)

^f Composition of the GECSA ^*  (France)

^g Clinical and biological hospital units   (France)

^h Obstetrics and Gynecology Service Hospital of Arcachon   (France)

ⁱ Dax Hospital   (France)

^j Bayonne Hospital   (United States)

^k Libourne Hospital   (France)

^l Centre Hospitalier de Mont de Marsan   (France)

^m Pau Hospital   (Spain)

ⁿ Unit of Medical Information and Public Health   (France)

^o Centre Hospitalier Villeneuve sur Lot   (France)

^p NONE

more..

Author keywords

AIDS; Antiretroviral therapy; Brazil; Cohort study; France; HIV; Hospitalization; Severe morbidity

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BACTERIAL INFECTION; BRAZIL; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DESCRIPTIVE RESEARCH; DISEASE ASSOCIATION; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; FOLLOW UP; FRANCE; GASTROINTESTINAL DISEASE; GYNECOLOGIC DISEASE; HEALTH CARE ACCESS; HEMATOLOGIC DISEASE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INJURY; KIDNEY DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL ANALYSIS; MENTAL DISEASE; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; NON ACQUIRED IMMUNE DEFICIENCY SYNDROME; PARASITOSIS; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; RHEUMATIC DISEASE; SKIN DISEASE; SYMPTOMATOLOGY; VIRUS INFECTION; VIRUS TRANSMISSION; ACQUIRED IMMUNODEFICIENCY SYNDROME; COMPARATIVE STUDY; COMPLICATION; EPIDEMIOLOGY; HOSPITAL; MIDDLE AGED;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; BRAZIL; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FRANCE; HIV INFECTIONS; HOSPITALIZATION; HOSPITALS; HUMANS; MALE; MIDDLE AGED; MORBIDITY; QUALITY OF LIFE;

EID: 84901454172     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-278     Document Type: Article

References (42)

1. Kaulich-Bartz J, Dam W, May MT, Lederberger B, Widmer U, Phillips AN, Grabar S, Mocroft A, Vilaro J, van Sighem A, Moreno S, Dabis F, Monforte AD, Teira R, Ingle SM, Sterne JA, . Writing Committee for the Antiretroviral Therapy Cohort C Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS 2013, 27(10):1641-1655. 10.1097/QAD.0b013e3283601199, 3678894, 23449349, Writing Committee for the Antiretroviral Therapy Cohort C.
2. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, Jougla E, Semaille C, Morlat P, Salmon D, Cacoub P, Chene G. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immunodefic Syndr 2008, 48(5):590-598.
3. Berry SA, Fleishman JA, Moore RD, Gebo KA. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr 2012, 59(4):368-375. 10.1097/QAI.0b013e318246b862, 3299935, 22240460.
4. ART-CC Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010, 50(10):1387-1396. 3157754, 20380565, ART-CC.
5. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010, 55(2):262-270. 10.1097/QAI.0b013e3181e9be6b, 20700060.
6. Pacheco AG, Tuboi SH, May SB, Moreira LF, Ramadas L, Nunes EP, Mercon M, Faulhaber JC, Harrison LH, Schechter M. Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil. J Acquir Immunodefic Syndr 2009, 51(5):624-630.
7. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J. Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites. HIV Med 2010, 11(9):554-564. 10.1111/j.1468-1293.2010.00824.x, 20345879.
8. Buchacz K, Baker RK, Moorman AC, Richardson JT, Wood KC, Holmberg SD, Brooks JT. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008, 22(11):1345-1354. 10.1097/QAD.0b013e328304b38b, 18580614.
9. Yehia BR, Fleishman JA, Wilson L, Hicks PL, Gborkorquellie TT, Gebo KA. Incidence of and risk factors for bacteraemia in HIV-infected adults in the era of highly active antiretroviral therapy. HIV Med 2010, 12(9):535-543.
10. Bonnet F, Chene G, Thiebaut R, Dupon M, Lawson-Ayayi S, Pellegrin JL, Dabis F, Morlat P. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med 2007, 8(8):547-554. 10.1111/j.1468-1293.2007.00508.x, 17944688.
11. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Menan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 2012, 54(5):714-723. 10.1093/cid/cir898, 3275759, 22173233.
12. Thiebaut R, Morlat P, Jacqmin-Gadda H, Neau D, Mercie P, Dabis F, Chene G. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidemiologie du SIDA en Aquitaine (GECSA). AIDS 2000, 14(8):971-978. 10.1097/00002030-200005260-00008, 10853978.
13. Grinsztejn B, Veloso VG, Friedman RK, Moreira RI, Luz PM, Campos DP, Pilotto JH, Cardoso SW, Keruly JC, Moore RD. Early mortality and cause of deaths in patients using HAART in Brazil and the United States. AIDS 2009, 23(16):2107-2114. 10.1097/QAD.0b013e32832ec494, 3790467, 19770698.
14. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.
15. Ballinger GA. Using generalized estimating equations for longitudinal data analysis. Organ Res Methods 2004, 7(2):127-150.
16. Grinsztejn B, Veloso VG, Pilotto JH, Campos DP, Keruly JC, Moore RD. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil. J Acquir Immune Defic Syndr 2007, 45(5):515-520. 10.1097/QAI.0b013e3180decb6a, 17558332.
17. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Wirtz V, Lataillade M, Absalon J, McGrath D. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010, 53(3):323-332. 10.1097/QAI.0b013e3181c990bf, 20032785.
18. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369(9569):1261-1269. 10.1016/S0140-6736(07)60597-2, 17434401.
19. Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, Rockstroh J, Stoehr A, Vetter N, Yeni P, Parys W, Vangeneugden T. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007, 21(4):395-402. 10.1097/QAD.0b013e328013d9d7, 17301557.
20. DeJesus E, Rockstroh JK, Lennox JL, Saag MS, Lazzarin A, Zhao J, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials 2012, 13(4):228-232. 10.1310/hct1304-228, 22849964.
21. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011, 53(11):1130-1139. 10.1093/cid/cir626, 21998280.
22. Crum-Cianflone NF, Grandits G, Echols S, Ganesan A, Landrum M, Weintrob A, Barthel R, Agan B. Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use?. J Acquir Immune Defic Syndr 2010, 54(3):248-257. 10.1097/QAI.0b013e3181c8ef22, 2911973, 20658748.
23. Japiassu AM, Amancio RT, Mesquita EC, Medeiros DM, Bernal HB, Nunes EP, Luz PM, Grinsztejn B, Bozza FA. Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients. Crit Care 2010, 14(4):R152. 10.1186/cc9221, 2945136, 20698966.
24. Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, Boccara F, Costagliola D. HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals. Clin Infect Dis 2012, 55(4):600-607. 10.1093/cid/cis489, 22610928.
25. Gebo KA, Diener-West M, Moore RD. Hospitalization rates differ by hepatitis C satus in an urban HIV cohort. J Acquir Immune Defic Syndr 2003, 34(2):165-173. 10.1097/00126334-200310010-00006, 14526205.
26. Mocroft A, Monforte A, Kirk O, Johnson MA, Friis-Moller N, Banhegyi D, Blaxhult A, Mulcahy F, Gatell JM, Lundgren JD. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med 2004, 5(6):437-447. 10.1111/j.1468-1293.2004.00250.x, 15544697.
27. Nunez-Fernandez C, Martin-Carbonero L, Valencia ME, Aguilera J, Garcia-Samaniego J, Gonzalez-Lahoz J, Soriano V. Liver complications have reached a plateau as cause of hospital admission and death in HIV patients in Madrid. AIDS Res Hum Retroviruses 2009, 25(4):383-385. 10.1089/aid.2008.0242, 19320566.
28. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chene G, Morlat P. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 2009, 48(5):633-639. 10.1086/596766, 19202627.
29. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005, 97(6):425-432. 10.1093/jnci/dji072, 15770006.
30. Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, Plaisance N, Tissot-Dupont H, Boue F, Lang JM, Costagliola D. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003, 21(18):3447-3453. 10.1200/JCO.2003.01.096, 12972519.
31. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan BK, Wegner S. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009, 23(1):41-50. 10.1097/QAD.0b013e328317cc2d, 2727153, 19050385.
32. Clifford GM, Lise M, Franceschi S, Egger M, Bouchardy C, Korol D, Levi F, Ess S, Jundt G, Wandeler G, Fehr J, Schmid P, Battegay M, Bernasconi E, Cavassini M, Calmy A, Keiser O, Schoni-Affolter F. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer 2012, 106(3):447-452. 10.1038/bjc.2011.558, 3273350, 22240797.
33. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009, 10(12):1152-1159. 10.1016/S1470-2045(09)70282-7, 19818686.
34. Sigel K, Wisnivesky J, Gordon K, Dubrow R, Justice A, Brown ST, Goulet J, Butt AA, Crystal S, Rimland D, Rodriguez-Barradas M, Gibert C, Park LS, Crothers K. HIV as an independent risk factor for incident lung cancer. AIDS 2012, 26(8):1017-1025. 10.1097/QAD.0b013e328352d1ad, 3580210, 22382152.
35. Shebl FM, Engels EA, Goedert JJ, Chaturvedi AK. Pulmonary infections and risk of lung cancer among persons with AIDS. J Acquir Immune Defic Syndr 2010, 55(3):375-379. 10.1097/QAI.0b013e3181eef4f7, 2955766, 20736841.
36. Benard A, Bonnet F, Tessier JF, Fossoux H, Dupon M, Mercie P, Ragnaud JM, Viallard JF, Dabis F, Chene G. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS 2007, 21(7):458-468. 10.1089/apc.2006.0142, 17651027.
37. Elzi L, Spoerl D, Voggensperger J, Nicca D, Simcock M, Bucher HC, Spirig R, Battegay M. A smoking cessation programme in HIV-infected individuals: a pilot study. Antivir Ther 2006, 11(6):787-795.
38. Leutscher PD, Stecher C, Storgaard M, Larsen CS. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand J Infect Dis 2013, 45(8):645-651. 10.3109/00365548.2013.773067, 23427878.
39. Lanoy E, Mary-Krause M, Tattevin P, Perbost I, Poizot-Martin I, Dupont C, Costagliola D. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 2007, 12(1):89-96.
40. Moreira RI, Luz PM, Struchiner CJ, Morgado M, Veloso VG, Keruly JC, Grinsztejn B, Moore RD. Immune status at presentation for HIV clinical care in Rio de Janeiro and Baltimore. J Acquir Immune Defic Syndr 2011, 57(Suppl 3):S171-S178. 3170137, 21857314.
41. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011, 53(11):1120-1126. 10.1093/cid/cir627, 21998278.
42. Torres TS, Cardoso SW, Velasque Lde S, Marins LM, De Oliveira MS, Veloso VG, Grinsztejn B. Aging with HIV: an overview of an urban cohort in Rio de Janeiro (Brazil) across decades of life. Braz J Infect Dis 2013, 17(3):324-331. 10.1016/j.bjid.2012.10.024, 23602466.